Improve Manufacturing Consistency Through Better Donor Selection
As allogeneic cell therapies progress toward commercial-scale manufacturing, donor variability is emerging as a critical factor influencing process robustness, product consistency, yield, and scale-up potential.
The 4th Donor Selection & Cell Source Summit provides a dedicated forum for manufacturing, technical operations, and process development leaders to explore how donor selection, qualification, and characterization strategies can improve manufacturing performance and support long-term commercial success.
Why Attend?
Join peers from across the allogeneic cell therapy community to discover how leading organizations are:
Selecting donors that increase yield and reduce manufacturing failures
Minimizing variability to improve batch-to-batch consistency
Improving batch consistency to accelerate product release confidence
Securing donor supply to enable confident commercial scale-up
Choosing higher-quality starting materials to maximize operational efficiency
Leave With Insights On:
- Identifying donor attributes that unlock higher manufacturing yields
- Reducing donor-driven variability for more consistent product quality
- Emerging screening strategies to minimize manufacturing risk
- Scalable donor frameworks that support confident commercial expansion
Explore the Full Event Guide
- Discover donor selection strategies from Cellectis, Mesoblast, Atara Bio, and Caribou Bio to improve clinical outcomes
- Explore donor sourcing from cord blood, PBMCs, and iPSCs to benchmark strategies, and gain clarity on where the field is moving
- Review the full agenda, speakers, and sessions to align team priorities
- Identify valuable networking opportunities to maximize connections with peers and providers